Patent USRE34026E successfully refreshed from Google Patents.
Patent US5456901A successfully refreshed from Google Patents.
US5456901A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liposomes as contrast agents for ultrasonic imaging
Assignee: Bristol Myers Squibb Pharma Co
•
Filing: 1995-02-28
•
Granted: 1995-10-10
•
Expires: 2015-02-28
Abstract
Abstract Liposomes suitable as ultrasound contrast agents which contain media of various types including gases, gaseous precursors activated by pH, temperature or pressure, as well as other solid or liquid contrast enhancing agents, are described. Methods of using the same as ultrasound contrast agents are also disclosed. The present invention also comprises novel methods for synthesizing liposomes having encapsulated therein gases.
Inventors
- 👤 Evan C. Unger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:21
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K41/00; A61K41/0028; A61K41/0052; A61K47/00; A61K47/50; A61K47/69; A61K47/6905; A61K47/6911; A61K47/6921; A61K47/6941; A61K49/00; A61K49/06; A61K49/18; A61K49/1806; A61K49/1815; A61K49/22; A61K49/222; A61K49/223; A61K49/227; A61K9/1277; A61K9/1278
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
70 words
A method of providing an image of an internal region of a patient comprising: (a) administering to the patient a liposome having encapsulated therein a solid contrast enhancing agent selected from the group consisting of magnetite and solid iodine particles, or a liquid contrast enhancing agent selected from the group consisting of solubilized iodinated compounds; and (b) scanning the patient using ultrasonic imaging to obtain visible images of the region.
Claim 2
Independent Claim
70 words
A method of providing an image of an internal region of a patient comprising: (a) administering to the patient a liposome having encapsulated therein a solid contrast enhancing agent selected from the group consisting of magnetite and solid iodine particles, or a liquid contrast enhancing agent selected from the group consisting of solubilized iodinated compounds; and (b) scanning the patient using ultrasonic imaging to obtain visible images of the region.
Claim 3
Dependent Claim
29 words
The method according to claim 1 wherein said liposomes are administered intravascularly, and the vesicles have a mean outer diameter of between about 30 nanometers and about 2 microns.
Claim 4
Dependent Claim
18 words
The method according to claim 2; wherein the patient is scanned in the area of the patient's heart.
Claim 5
Dependent Claim
19 words
The method according to claim 2 wherein the patient is scanned in the area of the patient's arterial system.
Claim 6
Dependent Claim
19 words
The method according to claim 2 wherein the patient is scanned in the area of the patient's venous system.
Claim 7
Dependent Claim
21 words
The method according to claim 2 wherein the patient is scanned in the area of the patient's liver, spleen and kidney.
Claim 8
Dependent Claim
28 words
The method according to claim 1 wherein the liposomes are administered other than intravascularly and have a mean outer diameter between about 2 microns and about 10 microns.
Claim 9
Dependent Claim
47 words
The method of claim 1 wherein the liposomes are comprised of lipids of either natural or synthetic origin selected from the group consisting of fatty acids, lysolipids, dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, phosphatidylinositol, sphingomyelin, lysolipids, cholesterol, cholesterol hemisuccinate, glycosphingolipids, glycolipids, glucolipids, sulphatides, and tocopherol hemisuccinate.
Claim 10
Independent Claim
73 words
A method for diagnosing the presence of diseased tissue in a patient comprising: (a) administering to the patient a liposome having encapsulated therein a solid contrast enhancing agent selected from the group consisting of magnetite and solid iodine particles, or a liquid contrast enhancing agent selected from the group consisting of solubilized iodinated compounds; and (b) scanning the patient using ultrasonic imaging to obtain visible images of any diseased tissue in the patient.
Claim 11
Independent Claim
73 words
A method for diagnosing the presence of diseased tissue in a patient comprising: (a) administering to the patient a liposome having encapsulated therein a solid contrast enhancing agent selected from the group consisting of magnetite and solid iodine particles, or a liquid contrast enhancing agent selected from the group consisting of solubilized iodinated compounds; and (b) scanning the patient using ultrasonic imaging to obtain visible images of any diseased tissue in the patient.
Claim 12
Dependent Claim
25 words
A method according to claim 1 wherein said contrast enhancing agent is a solid selected from the group consisting of magnetite and solid iodine particles.
Claim 13
Dependent Claim
23 words
A method according to claim 11 wherein said solid iodine particles are selected from the group consisting of iodipamide ethyl ester and metricate.
Claim 14
Dependent Claim
15 words
A method according to claim 11 wherein said solid iodine particles are iodipamide ethyl ester.
Claim 15
Dependent Claim
23 words
A method according to claim 1 wherein said contrast enhancing agent is a liquid selected from the group consisting of solubilized iodinated compounds.
Claim 16
Dependent Claim
29 words
A method according to claim 9 wherein said liposomes are administered intravascularly, and the vesicles have a mean outer diameter of between about 30 nanometers and about 2 microns.
Claim 17
Dependent Claim
18 words
A method according to claim 14 wherein the patient is scanned in the area of the patient's heart.
Claim 18
Dependent Claim
19 words
A method according to claim 14 wherein the patient is scanned in the area of the patient's arterial system.
Claim 19
Dependent Claim
19 words
A method according to claim 14 wherein the patient is scanned in the area of the patient's venous system.
Claim 20
Dependent Claim
21 words
A method according to claim 14 wherein the patient is scanned in the area of the patient's liver, spleen and kidney.
Claim 21
Dependent Claim
28 words
A method according to claim 9 wherein the liposomes are administered other than intravascularly and have a mean outer diameter between about 2 microns and about 10 microns.
Claim 22
Dependent Claim
41 words
A method of claim 9 wherein the liposome is comprised of lipid selected from the group consisting of fatty acids, lysolipids, dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, phosphatidylinositol, sphingomyelin, lysolipids, cholesterol, cholesterol hemisuccinate, glycosphingolipids, glycolipids, glucolipids, sulphatides, and tocopherol hemisuccinate.
Claim 23
Dependent Claim
25 words
A method according to claim 9 wherein said contrast enhancing agent is a solid selected from the group consisting of magnetite and solid iodine particles.
Claim 24
Dependent Claim
23 words
A method according to claim 20 wherein said solid iodine particles are selected from the group consisting of iodipamide ethyl ester and metricate.
Claim 25
Dependent Claim
15 words
A method according to claim 22 wherein said solid iodine particles are iodipamide ethyl ester.
Claim 26
Dependent Claim
23 words
A method according to claim 9 wherein said contrast enhancing agent is a liquid selected from the group consisting of solubilized iodinated compounds.
References Cited (Backward Citations)
US3532500A
Cited
US3873564A
Cited
US4089801A
Cited
US4162282A
Cited
US4229360A
Cited
US4224179A
Cited
US4229360B1
Cited
US4192859A
Cited
US4310506A
Cited
WO1980002365A1
Cited
US4276885A
Cited
US4310505A
Cited
US4344929A
Cited
US4315514A
Cited
US4331654A
Cited
US4442843A
Cited
WO1982001642A1
Cited
US4681119A
Cited
US4657756A
Cited
US4533254A
Cited
US4586512A
Cited
US4426330A
Cited
US4534899A
Cited
US4569836A
Cited
US4466442A
Cited
EP0107559A1
Cited
US4646756A
Cited
US4603044A
Cited
US4718433A
Cited
US4572203A
Cited
US4900540A
Cited
US4544545A
Cited
WO1985001161A1
Cited
US4675310A
Cited
US4728575A
Cited
US4658828A
Cited
US5008050A
Cited
WO1986000238A1
Cited
US4620546A
Cited
WO1986001103A1
Cited
US4921706A
Cited
US4830858A
Cited
US4689986A
Cited
US4895719A
Cited
EP0216730A2
Cited
US4684479A
Cited
US4938947A
Cited
US4774958A
Cited
US4865836A
Cited
US4987154A
Cited
US4927623A
Cited
EP0231091A1
Cited
US4737323A
Cited
US4877561A
Cited
GB2193095A
Cited
US4728578A
Cited
US4776991A
Cited
JPS6360943A
Cited
US4781871A
Cited
US4790891A
Cited
US5195520A
Cited
US5049388A
Cited
US4863717A
Cited
EP0272091A2
Cited
US5000960A
Cited
US5219538A
Cited
EP0314763B1
Cited
WO1989005040A1
Cited
EP0324938A1
Cited
US4844882A
Cited
US4898734A
Cited
EP0338971A1
Cited
US5171755A
Cited
US4893624A
Cited
US5045304A
Cited
US4957656A
Cited
US5316771A
Cited
EP0361894A2
Cited
US5198225A
Cited
WO1990004943A1
Cited
US5114703A
Cited
WO1991000086A1
Cited
US5194266A
Cited
US5213804A
Cited
US5013556A
Cited
US5088499A
Cited
US5271928A
Cited
WO1991015244A2
Cited
EP0458745A1
Cited
US5215680A
Cited
US5310540A
Cited
WO1992010166A1
Cited
WO1992017212A1
Cited
WO1993005819A1
Cited
WO1993006869A1
Cited
WO1993013809A1
Cited
EP0554213A1
Cited
WO1993020802A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-10-09 | 1999-04-10 | 1999-10-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-10-09 | 2003-04-10 | 2003-10-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-10-09 | 2007-04-10 | 2007-10-10 | $7700.00 | Window Closed / Lapsed |